gms | German Medical Science

13. Jahrestagung der Gesellschaft für Arzneimittelforschung und Arzneimittelepidemiologie

Gesellschaft für Arzneimittelforschung und Arzneimittelepidemiologie

02.11. bis 03.11.2006, Berlin

From insurance claims data to the practice of optimizing the drug use of children

Meeting Abstract

  • corresponding author M. Pfannkuche - ZeS, Uni Bremen
  • T. Steimle - Techniker Krankenkasse, Hamburg
  • N. Lentges - Techniker Krankenkasse, Hamburg
  • F. Verheyen - Techniker Krankenkasse, Hamburg
  • G. Glaeske - ZeS, Uni Bremen

Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie e.V. (GAA). 13. Jahrestagung der Gesellschaft für Arzneimittelforschung und Arzneimittelepidemiologie. Berlin, 02.-03.11.2006. Düsseldorf: German Medical Science GMS Publishing House; 2006. Doc06gaa10

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 30. Oktober 2006

© 2006 Pfannkuche et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Context: The Techniker Krankenkasse (TK) strives to support the empowerment of its insurees by means of patient information and shared decision making tools. Developing a booklet about drug use in children aims to increase the awareness of parents regarding compliance and effectiveness of drug use in children.

Aim of the study: To evaluate and critically appraise drug regime in children.

Material and Method: A statutory health insurance company’s person specific but non-identifying prescription data from 2005 were analysed. Prescription data of children aged 12 or younger (809,032 insurees) were identified. The drugs were classified according the Rote Liste main index (RL).

Results: In 2005 85.3 % of the children received at least one prescription. The proportion of the adolescent and adults (aged 12 or older) with at least one prescription was 76.0 % respectively. Antitussives/expectorants (18.1 %), decongestants/sinusitis agents (13.3 %), antibiotics (11.5 %), analgetics/anti-inflammatory drugs (11.3 %) and broncholytics/antiasthmatic drugs (6.9 %) are the most frequent prescribed drugs for children. 66.6 % of the drugs prescribed were over-the-counter-drugs (compared with 4.5% in adolescents and adults). However, three of the ten most prescribed drugs (Prospan®, Mucosolvan®, Spasmo-Mucosolvan®) lack convincing evidence of effectiveness. 1.6% of the prescribed sympathomimetics were used off-label.

Conclusion: Children represent other spectrums of diseases than adults and are particularly affected by acute infections. The high amount of antitussives and the proportion of off-label-use of sympathomimetics needs to be discussed in the context of rational and safe drug therapy. Further investigation is needed to optimize the drug use in children.